TOLERABILITY OF A NEW HUMAN IMMUNE GLOBULIN SUBCUTANEOUS, 20% PREPARATION IN PRIMARY IMMUNODEFICIENCY DISEASES

被引：0
作者：
Gupta, S.
Stein, M.
Melamed, I.
Hussain, I.
Paris, K.
Engl, W.
Mccoy, B.
Rabbat, C.
Yel, L.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2016年 / 117卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
O015
引用
收藏
页码：S5 / S6
页数：2
相关论文
共 50 条
  • [41] Safety, Tolerability and Pharmacokinetics (PK) of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Interim Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiencies (PI)
    Krivan, Gergely
    Borte, Michael
    Marodi, Laszlo
    Derfalvi, Beata
    Dicso, Ferenc
    Engl, Werner
    Leibl, Heinz
    McCoy, Barbara
    Schiff, Richard I.
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (03) : 384 - 384
  • [42] Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naive patients with primary immunodeficiency diseases
    Li, Zhaoyang
    Dumas, Todd
    Berry, N. Seth
    McCoy, Barbara
    Yel, Leman
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 100
  • [43] Model-Based Simulation of Varied Subcutaneous Immune Globulin (Human), 20% (Ig20Gly) Loading and Maintenance Dosing Regimens in Immunoglobulin-Naive Patients with Primary Immunodeficiency Diseases
    Li, Zhaoyang
    Dumas, Todd
    McCoy, Barbara
    Berry, N. Seth
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2021, 41 (SUPPL 1) : S96 - S97
  • [44] Immune globulin subcutaneous, human - klhw 20% solution (Xembify®, IGSC-C 20%) has a positive safety and tolerability profile in an open-label, multicenter, phase 3 study in primary immunodeficiency (PI)
    Wedner, H. James
    Sleasman, John
    Lumry, William
    Hussain, Iftikhar
    Harris, James
    Mondou, Elsa
    Lin, Jiang
    Hames, Carrie
    Querolt, Montse
    Stein, Mark
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB31 - AB31
  • [45] Efficacy, Safety and Tolerability of a New 10% Liquid Intravenous Immune Globulin [IGIV 10%] in Patients with Primary Immunodeficiency
    Joseph A. Church
    Heinz Leibl
    Mark R. Stein
    Isaac R. Melamed
    Arye Rubinstein
    Lynda C. Schneider
    Richard L. Wasserman
    Borislava G. Pavlova
    Karl Birthistle
    Marianne Mancini
    Sandor Fritsch
    Lisa Patrone
    Kerry Moore-Perry
    Hartmut J. Ehrlich
    Journal of Clinical Immunology, 2006, 26 : 388 - 395
  • [46] Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency
    Church, Joseph A.
    Leibl, Heinz
    Stein, Mark R.
    Melamed, Isaac R.
    Rubinstein, Arye
    Schneider, Lynda C.
    Wasserman, Richard L.
    Pavlova, Borislava G.
    Birthistle, Karl
    Mancini, Marianne
    Fritsch, Sandor
    Patrone, Lisa
    Moore-Perry, Kerry
    Ehrlich, Hartmut J.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2006, 26 (04) : 388 - 395
  • [47] Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease
    Wasserman, R. L.
    Irani, A. -M.
    Tracy, J.
    Tsoukas, C.
    Stark, D.
    Levy, R.
    Chen, J.
    Sorrells, S.
    Roberts, R.
    Gupta, S.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2010, 161 (03) : 518 - 526
  • [48] Efficacy, Safety, and Tolerability of Prometics Immune Globulin Intravenous (Human) 10% (Prometic 10% IGIV) in Adult and Pediatric Subjects with Primary Immunodeficiency Diseases (PIDD)
    Kanekar, Shalini
    Moy, James
    Trybul, Diane
    Parker, Joseph
    Albert, Gary
    JOURNAL OF CLINICAL IMMUNOLOGY, 2018, 38 (03) : 358 - 358
  • [49] 20% subcutaneous immunoglobulin for patients with primary immunodeficiency diseases: A systematic review
    Song, Jie
    Zhang, Lingli
    Li, Youping
    Quan, Shuyan
    Liang, Yi
    Zeng, Linan
    Liu, Yi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2015, 25 (02) : 457 - 464
  • [50] INTRAVENOUS IMMUNE GLOBULIN IN PRIMARY IMMUNODEFICIENCY
    HAENEY, M
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1994, 97 : 11 - 15
12345